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Implication for health policy/practice/research/medical education:
In a study on 50 β-thalassemia major patients (27 individuals receiving desferal and 23 with deferasirox) no significant difference 
of renal function, hypercalciuria, glycosuria and proteinuria between two groups was detected.
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Introduction: Deferasirox is a new oral iron chelating agent which has been administered in 
β-thalassemia major patients in last few years. There is some reports regarding nephrotoxicity 
of this agent; however, no comparative study has been conducted yet.
Objectives: The aim of this study was to compare the prevalence of kidney dysfunction in 
β-thalassemia major patients receiving either desferal or deferasirox as iron chelating agents.
Patients and Methods: In this cross-sectional study, adult patients with β-thalassemia 
major who received 25 mg/kg/d of desferal or 25 mg/kg/d of deferasirox were studied. We 
compared them for serum calcium (Ca), creatinine (Cr) levels and 24 hours urine collection 
for proportion of Ca and protein. Estimated glomerular filtration rate (eGFR) was calculated 
by Cockcroft-Gault formula. 
Results: Twenty-seven patients receiving desferal and 23 patients receiving deferasirox were 
evaluated. There was no significant difference of calciuria (P = 0.19), glycosuria (P = 0.508), 
mean 24-hour urine proteinuria (P = 0.44), mean serum Cr (P = 0.47), serum Ca level (P = 
0.067) and mean eGFR (P = 0.42) between two groups. 
Conclusion: There is no significant difference of hypercalciuria, glycosuria, mean eGFR, 
proteinuria, and also serum Cr between β-thalassemia major patients who received desferal 
or deferasirox.
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Introduction
Thalassemia is a form of inherited hematologic disorder 
of hemoglobin synthesis due to α/β-globin chain 
imbalance. It leads to ineffective hematopoiesis. The 
most severe form is β-thalassemia major which requires 
long-term transfusion to correct anemia. Since there 
is no physiologic active mechanism for the excretion 
of iron, regular transfusions cause iron overload (1). 
Excess iron accumulates in heart, spleen, liver and leads 
to overproduction of free radicals; which causes organ 
damages (2-4).
Since, the main reason of death in patients with 
β-thalassemia major is heart failure due to myocardial 
iron deposition, iron chelating agents have increased the 
life expectancy of patients (5-7).
Regular administration of deferoxamine as a chelating 
agent first introduced in 1960, nearly doubled lifetime of 
patients (8-10). Deferoxamine needs slow subcutaneous 
infusion over 8-12 hours with high lifetime costs (9-11).
In the recent two decades, introduction of two oral 
chelating agents; deferiprone and deferasirox, much 
preferred by patients. These two drugs have improved 
treatment of β-thalassemia major patients significantly 
(10).
The prevalence of hypercalciuria and renal stones is higher 
in patients with β-thalassemia major (12,13). Studies have 
shown that prevalence of renal stone is higher in patients 
using deferasirox or deferiprone with unknown reason 
(14,15).
Higher urinary excretion of calcium (Ca) increases the 
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risk of Ca phosphate and Ca oxalate stone formation. 
The risk of stones increases with increased urinary Ca 
excretion >100 mg/d. However, there is no unique cut off 
and definition for hypercalciuria (16,17).
There are limited data considering the effect of thalassemia 
on kidney. Recent data suggests that deferasirox may be 
nephrotoxic, since high doses intravenous injections of 
deferoxamine could have adverse renal effects (18).
Since, there are not enough studies on side effects of 
chelation therapy in patients with β-thalassemia major, 
we compared the prevalence of renal dysfunction in 
patients with β-thalassemia major receiving desferal 
(deferoxamine) compared to deferasirox.
Objectives
The aim of this study was to compare the renal effects 
of desferal versus deferasirox in β-thalassemia major 
patients.
Patients and Methods
Twenty-seven patients injecting 25 mg/kg/d of desferal 
and 23 patents receiving 25 mg/kg/d of deferasirox 
orally, who also took 1-3 Ca carbonate tablets per day as 
supplement, were selected based on systematic random 
sampling method. Serum Ca and creatinine (Cr) were 
checked and 24 hours urine was collected to analyze 
proportion of protein and Ca. Random urine analysis was 
done and glycosuria was checked by dipstick.
Ethical issues
The research followed the tenets of the Declaration of 
Helsinki. Informed consent was obtained. The study 
protocol was approved by the Ethics Committee of Iran 
University of Medical Science (#93-02-30-24649). 
Statistical analysis
Analysis was performed in SPSS version 22 software (IBM; 
Chicago, IL, USA). We used mean and standard deviation 
(SD) or median and interquartile range (IQR) to describe 
numerical variables and relative frequency percentage to 
describe the nominal or categorical variables. Chi-square 
test was applied to compare qualitative outcomes between 
two groups and independent t test to compare quantitative 
outcomes between two groups. The level of significance 
was 0.05 for two-sided tests.
Results
Twenty-seven patients receiving daily desferal injection 
and 23 patients receiving daily oral deferasirox were 
evaluated. In desferal group 55.5% were male and in 
deferasirox group 52.17% were male. 
Patients in desferal group received 850 mg Ca averagely, 
and patients in deferasirox group received 800 mg 
averagely which was not significantly different between 
the groups (P = 0.78).
Overall 70% of patients had hypercalciuria by definition 
of 24 hours urine Ca >100 mg. The proportion of 24 hours 
urine Ca of more than100 mg/d is significantly higher in 
female group who received desferal (Table 1). 
Additionally, the proportion of glycosuria was different 
among two groups. In desferal group, only 7.4% had 
glycosuria while, in deferasirox group 13% had glycosuria, 
however, it is not significant (P = 0.508).
The estimated glomerular filtration rate (eGFR) in 
desferal group and deferasirox group were 120.45 ± 35.25 
mL/min/1.73 m2 and 112.80 ± 31.27) mL/min/1.73 m2 
respectively (P = 0.42). Accordingly 24 hours urine protein 
excretion in desferal and deferasirox groups were 110 mg/
day and 188.09 mg/d respectively (P = 0.44).
Furthermore, the mean serum Cr level between two 
groups were 0.68 ± 0.12 mg/dL and 0.67 ± 0.11 mg/dL 
respectively (P = 0.47). Likewise, the mean serum Ca in 
desferal and deferasirox groups were 8.11±0.32 mg/dL 
and 8.04 ± 0.2 mg/dL respectively (P = 0.47).
Discussion
The result of our study showed that mean 24 hours urine 
Ca was not significantly different between groups. Among 
patients who had hypercalciuria, 60% were administered 
desferal and 40% received deferasirox, however, this 
difference was not significant. It should be noted that our 
study was conducted on a small proportion of patients. 
Table 1. Comparison of laboratory data between two groups
Gender Variables Desferal group Deferasirox group P value
Male Urine calcium (mg)
<100 26.6% 25%
0.92
≥100 73.3% 75%
Female Urine calcium (mg)
<100 16.6% 54.5%
0.06
≥100 83.3% 45.4%
Male Urine calcium (mg)
<250 86.7% 66.7%
0.35
≥250 13.3% 33.3%
Female Urine calcium (mg)
<250 91.7% 81.8%
0.59
≥250 8.3% 18.2%
Glycosuria (mg) 7.4% 13% 0.51
GFR (mL/min/1.73 m2) 120.45 ± 35.25b 112.80 ± 31.27b 0.42
Proteinuria (mg) 110 ± 91.77b 188.09 ± 514.38b 0.44
Serum Cr (mg/dL) 0.68 ± 0.12b 0.67 ± 0.11b 0.47
b Mean± SD.
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Additionally, the proportion of glycosuria, proteinuria 
and eGFR was not significantly different among groups. 
Several studies have reported tubular dysfunctions 
– including proteinuria, hypercalciuria, and 
hyperphosphaturia – in thalassemia patients with normal 
GFR (19-21). In our study, the GFR of all patients were in 
normal range.
Numerous studies have reported concerns on the potential 
nephrotoxic effects of deferasirox. Tubular dysfunctions 
and proximal renal tubular dysfunction (Fanconi 
syndrome) have also been reported among deferasirox 
users (21).
Pathologic studies on rats have shown that deferasirox 
could cause vacuolization of proximal tubular epithelial 
cells and has direct toxic effect on cortical tubular cells. 
Acute tubular necrosis and tubular dysfunction was 
reported (22).
Cianciulli et al studied 19 patients with thalassemia 
who had administered deferoxamine. They found 
excreting large amounts of beta-2-microglobulin which 
was positively correlated with duration and dosage of 
therapy (23).
A phase III clinical trial comparing deferoxamine and 
deferasirox showed a rise in serum Cr in 38% of patients 
receiving deferasirox (mostly at doses of 20 and 30 mg/
kg and in patients who had the most dramatic decrease 
in liver iron concentration and serum ferritin level). 
However, 14% of patients who received deferasirox had a 
similar increase in serum Cr. Importantly, this rises were 
occasionally transient and mostly within the normal range 
(24,25).
Conclusion
The proportion of hypercalciuria and glycosuria, 
proteinuria and eGFR were not significantly different in 
β-Thalassemia major patients with receiving desferal or 
deferasirox as a chelating agent.
Limitations of the study
The low proportion of patients is a limitation of our 
study. We hope that such studies will be repeated with 
larger sample size to confirm the renal safety of oral iron 
chelating agents for widespread use.
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